X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    New Delivery Path Brings To Light Efficacy of Immunotherapy

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    New Delivery Path Brings To Light Efficacy of Immunotherapy

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

Luye Pharma Acquired 57.98% Stake of Beijing Jialin Pharmaceutical

Yuvraj_pawp by Yuvraj_pawp
4th September 2014
in Americas, News

The board of directors of Luye Pharma Group Ltd., announced yesterday that the Company had entered into an agreement to purchase 57.98% stake of Beijing Jialin Pharmaceutical Co., Ltd. (Jialin Pharmaceutical) for an aggregate consideration of RMB 3.68 billion in cash. The acquisition will add another key product to the Company’s portfolio and enrich product line of cardiovascular system, which is the strategic therapeutic focus of the Company. This acquisition will further strengthen Company’s market position and competitive advantage in cardiovascular system, especially in the area of lipid regulators, and thus maximize the Company’s size and strengths swiftly.

The Company focuses on the development, production, marketing and selling of innovative products in oncology, cardiovascular system, and alimentary tract and metabolism. Cardiovascular system is one of the Company’s key therapeutic area. Jialin Pharmaceutical is a leading player in the PRC pharmaceutical sector principally engaged in the pharmaceutical products in cardiovascular systems. Its leading product in cardiovascular system has become the main product in the area of lipid regulators in China. In addition, Jialin Pharmaceutical has a variety of products in cardiovascular system and its key areas are in tandem with the Company.

According to China Medical and Pharmaceutical Economic Information Network (MENET), cardiovascular system was the third largest overall therapeutic area for pharmaceutical products in China in 2013 in terms of revenue, accounting for 14.4% of the market. The Company’s key cardiovascular system products include Xuezhikang, which is the most influential and best-selling lipid regulators Chinese medicine. Xuezhikang is listed in the National List of Essential Drugs and enjoys exclusivity in China. Jialin Pharmaceutical has the leading product in cardiovascular system .The Company believes that the acquisition will supplement the Company’s already existing cardiovascular system product portfolio, help drive the Company’s market share, significantly increase its strategic competitiveness in the cardiovascular system market, especially in the area of lipid regulators. Meanwhile, the Company has Beixin((acarbose capsules used in the treatment of type 2 diabetes mellitus)–core product in alimentary tract and metabolism. The combination of three products will create substantial synergies and considerably strengthen the Company’s competitive advantage in the key strategic areas of the PRC cardiovascular system and alimentary tract and metabolism market.

The Company has a well-established nationwide sales and distribution network across 30 provinces, municipalities and autonomous regions in China. Jialin Pharmaceutical has also established a wide-coverage sales network through which it sells its products across China. Through the acquisition, the Company can further enhance its sales and marketing coverage and synergies, and take advantages of the multiple channels offered by the combined network.  

The Company develops innovative products on the back of its strong research and development capability, and believes that this will form the basis of the Company’s long-term competitiveness and serve as the drivers for the Company’s future growth and development. Jialin Pharmaceutical is a national high-tech enterprise and has rich experience and strong capabilities in product R&D. The acquisition will further enhance the Company’s research and development capability and provide valuable support to the Company’s pipeline R&D projects and other product development. 

The acquisition is in line with the Company’s strategic development needs in key therapeutic areas, key product lines, marketing and product research and development. The acquisition is conducive to maximizing the size and strength of the Company and solidifying the Company’s position in cardiovascular system. The combination of the Company and the Jialin Pharmaceutical will produce considerable synergies and fresh impetus to the Company’s better development in cardiovascular system in the future.

Tags: AmericaLuye Pharma Acquired 57.98% Stake of Beijing Jialin Pharmaceutical
Previous Post

CleveXel Pharma, Guilin Pharmaceutical partner to speed up development of anti-malarial products

Next Post

Bayer seeks marketing authorisation of aflibercept solution for injection in Japan

Related Posts

Drug Development

New Delivery Path Brings To Light Efficacy of Immunotherapy

1st April 2023
Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Next Post

Bayer seeks marketing authorisation of aflibercept solution for injection in Japan

Latest News

Drug Development

New Delivery Path Brings To Light Efficacy of Immunotherapy

1st April 2023
Cathay Cargo signs global airline partnership with Tower Cold Chain
Packaging & Logistic

Cathay Cargo signs global airline partnership with Tower Cold Chain

31st March 2023
Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In